Ozempic Lawsuit Update October 2026: 4,025 Cases, the Rule 702 Hearing, and What It Means for Your Claim
As of October 2026, more than 4,000 Ozempic and other GLP-1 lawsuits are pending in federal MDL 3094 before Judge Karen S. Marston in Pennsylvania. A September 2026 hearing ended with no ruling yet, no trial date set, and no settlement reached. People diagnosed with gastroparesis or intestinal blockage after GLP-1 use may still file, subject to their state's deadline.
Key facts:
- MDL No. 3094: 4,025 actions pending as of October 1, 2026, per the Judicial Panel on Multidistrict Litigation.
- Rule 702 hearing held September 14–18, 2026; no ruling yet, no trial schedule.
- No settlement exists — reported "$2 billion settlement" figures are speculation, not a court filing or company announcement.
- Since August 2025, gastroparesis claims require a gastric emptying study — symptoms alone are not enough.
- Defendants are Novo Nordisk and Eli Lilly. A separate vision-loss proceeding (MDL 3163, NAION claims) had 247 actions pending as of the same date.
For clear explainer coverage of legal topics, see Problem Solved.
What MDL 3094 Is and Where It Stands Right Now
MDL stands for multidistrict litigation: a federal procedure grouping thousands of similar lawsuits before one judge for coordinated pretrial work — shared documents and expert witnesses — while each plaintiff keeps an individual case. MDL No. 3094, formally In re: GLP-1 Receptor Agonists Products Liability Litigation, sits in the U.S. District Court for the Eastern District of Pennsylvania.
The litigation was reassigned to Judge Karen S. Marston in June 2026 after Judge Gene E.K. Pratter, the prior presiding judge, passed away in May 2026. In September 2026, Judge Marston held a multi-day Rule 702 hearing to test whether the plaintiffs' general-causation experts can testify at trial — a decision that will shape which claims proceed toward bellwether trials.
What the Lawsuits Actually Claim
The lawsuits allege that Novo Nordisk, Eli Lilly, and other GLP-1 manufacturers failed to adequately warn patients and prescribers that the drugs may cause severe gastrointestinal injuries: gastroparesis (stomach paralysis — the stomach empties too slowly), ileus (intestinal blockage), gastric stasis, and other serious digestive complications. The manufacturers deny the allegations.
The drugs named include Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, and Victoza. GLP-1 stands for glucagon-like peptide-1: medications originally approved for type 2 diabetes and later widely prescribed for weight management, which work in part by slowing how quickly food leaves the stomach.
The August 2025 Ruling That Changed Who Can Stay in the Case
In August 2025, Judge Marston issued a ruling with real practical consequences: any plaintiff claiming gastroparesis must show the diagnosis is based on a properly performed gastric emptying study — objective imaging showing delayed emptying — rather than symptoms alone. People who experienced severe vomiting, nausea, or abdominal pain but never received that diagnostic test may find their claims narrowed out of the litigation.
This is the most common reason valid claims stall: the injury is documented in emergency-room records, but the specific diagnostic study the court requires was never ordered. If you used a GLP-1 drug and suffered persistent vomiting or suspected stomach paralysis, ask your gastroenterologist about gastric emptying testing and keep every record.
Who May Still Be Able to File
New cases are still filed each month. People who may qualify for a case review were prescribed a GLP-1 medication and then suffered a diagnosed severe gastrointestinal injury — gastroparesis confirmed by a gastric emptying study, intestinal obstruction, or a related hospitalization.
Vision-loss (NAION) claims belong in the separate MDL 3163 track, not MDL 3094.
Your filing deadline is governed by your state's statute of limitations, not the MDL calendar. Most states give one to three years from when you discovered — or should have discovered — the injury, and waiting too long can permanently eliminate your right to compensation even while the MDL is still active.
What Compensation Could Look Like: Honest Numbers
Compensation varies widely by case, and no reliable public per-case figures exist — most pharmaceutical settlements are confidential, and no Ozempic or GLP-1 settlement has been reached, so any dollar range attached to "what your case is worth" is speculation. A recovery would depend on your specific facts: injury severity, medical costs, lost income, diagnostic evidence, and jurisdiction.
What is verifiable is how these cases are funded. Most mass-tort firms work on a contingency fee — usually 33% to 40% of any recovery, plus case costs — so you pay nothing upfront. For example, if a case resolved for $300,000 with a 33% fee, the fee would be $99,000, leaving $201,000 before costs are deducted. Reported "$2 billion settlement" figures are rumors: the court record shows no settlement, no fund, and no confirmed payouts.
Three Mistakes That Kill Otherwise Valid Claims
- No objective diagnosis. Symptoms in an ER discharge summary are not enough under the August 2025 ruling — you need the gastric emptying study or equivalent diagnostic documentation.
- Missing your state's deadline. The MDL stays open for years, but your personal statute of limitations does not. A claim filed one day late is over, regardless of its merits.
- Thin records. Keep every prescription, pharmacy record, ER note, and gastroenterology report. Gaps between the prescription and the injury are the defense's favorite argument.
What Happens Next in the Litigation
Settlement talks in pharmaceutical MDLs typically follow the first bellwether trial verdicts, which have not yet occurred — and no bellwether schedule has been set. The sequence to watch: the Rule 702 ruling, then bellwether case selection, then the first trials, and only then serious settlement negotiations. That process usually takes years, not months.
People with qualifying injuries can still have their cases evaluated and filed — a case review with a firm handling MDL 3094 claims is the practical next step. Similar mass-tort proceedings follow the same pattern; see our guides on the Zofran birth defect lawsuit, the Gardasil HPV vaccine lawsuit, and the Suboxone tooth decay lawsuit.
This article is general information, not legal or financial advice. Mass-tort law is state-specific; speak with a licensed attorney in your state about your situation.
Who Benefits From This — and Who Does Not
The GLP-1 litigation has 4,025 actions pending in MDL 3094 as of October 1, 2026, but no settlement — so it rewards documented claims and disappoints anyone looking for a quick payout.
Who benefits:
- People prescribed a named GLP-1 drug who developed gastroparesis supported by a properly performed gastric emptying study — since the August 2025 ruling, that study is required for a gastroparesis claim in MDL 3094 — symptoms alone are no longer enough
- People whose cases are already pending in MDL 3094 — the Judicial Panel reported 4,025 actions pending as of October 1, 2026, and the Rule 702 hearing developments affect which claims stay in the case
- People still within their state’s statute of limitations — new cases are still being filed, but your deadline is your state’s limit, not the MDL calendar, so a case evaluation now protects your options
- Families holding prescription and medical records for a named drug — Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, and Victoza are named, with Novo Nordisk and Eli Lilly as defendants
Who does not benefit:
- People with stomach symptoms but no gastric emptying study — under the August 2025 ruling, symptoms alone do not support a gastroparesis claim in MDL 3094
- People who never took one of the named GLP-1 drugs — the litigation is about those specific medicines, so use of another drug does not fit this case
- Anyone expecting a settlement payout now — as of October 2026 there is no settlement, no fund, and no confirmed payout figures in the GLP-1 litigation
- Vision-loss-only claims — those fall under the separate MDL 3163, which had 247 pending cases on the same date, rather than the MDL 3094 gastroparesis track
Related reading: a guide to who qualifies for a social media addiction claim and how to file.
Frequently Asked Questions
Is there an Ozempic settlement yet?
No. As of October 2026 there is no settlement, no fund, and no confirmed payout figures in the GLP-1 litigation.
How many Ozempic lawsuits are pending?
The Judicial Panel on Multidistrict Litigation reported 4,025 actions pending in MDL 3094 as of October 1, 2026; the separate vision-loss MDL 3163 had 247 pending on the same date.
Do I need a gastric emptying study to file?
Under the court's August 2025 ruling, a gastroparesis claim in the MDL must be supported by a properly performed gastric emptying study — symptoms alone are not enough.
Can I still file if the MDL has been going for years?
New cases are still being filed, but your deadline is your state's statute of limitations, not the MDL calendar. A case evaluation now protects your options.
Does the lawsuit cover Mounjaro and Wegovy too?
Yes. The litigation names multiple GLP-1 drugs, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, and Victoza, with Novo Nordisk and Eli Lilly as defendants.
Who is unlikely to qualify for the Ozempic litigation?
People who never took one of the named GLP-1 drugs, and people with stomach symptoms but no properly performed gastric emptying study — under the August 2025 ruling, symptoms alone do not support a gastroparesis claim in MDL 3094. Vision-loss claims are handled in the separate MDL 3163. And anyone expecting a payout now will be disappointed: as of October 2026 there is no settlement or fund.